---

Top Highlights for September 2013:  (Please click on news title to view details)

 

1.  Median deal multiple that Indian pharmaceutical Industry garnered is 4.12x of sales value against global average of 2.6x sales
2. India’s Apollo Hospital to receive $ 90.909 million investment from American PE firm KKR
3. One-third of India’s Gland Pharma likely to be acquired by US PE firm, KKR for $153.28 million
4. Indian VLCC form 70:30 JV with Kenya Sameer Group; investing $16.02 million to enter African wellness market
5. 26% stake of India Home Health Care acquired by US firm Bayada to expand expertise in areas like cancer care & care for children with special needs
6. Debiopharm Group in research agreement with TCG Lifesciences; will provide drug development expertise and funds
7. Swiss Biosafe partners with Indian companies to expand its stem cell banking business in India
8. Indian Life Science Organisation, Association of Biotech Led Enterprise and UK Trade & Investment signs a MoU to promote joint innovation in oncology discovery & delivery
9. Leading R&D spenders amongst the Indian pharma companies in 2012-13 have been Lupin Pharma (US$120 million), Dr Reddy’s Laboratories (US$120 million) and Cipla (US$67 million)

 

Aagami - Company updates : (Please click on news title to view details)

 

•  Aagami has moved to a new office

             Our new office is located at:

             Aagami, Inc.

             2135 City Gate Lane, Suite 300

             Naperville IL 60563
             Phone: +1-630-364-1837
             Mobile: +1-630-853-3520